How can drug discovery for psychiatric disorders be improved?
The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
Psychiatric disorders such as depression, anxiety and schizophrenia are leading causes of disability worldwide, and have a huge societal impact. However, despite the clear need for better therapies, and major advances in the understanding of the molecular basis of these disorders in recent years, efforts to discover and develop new drugs for neuropsychiatric disorders, particularly those that might revolutionize disease treatment, have been relatively unsuccessful. A multidisciplinary approach will be crucial in addressing this problem, and in the first Advances in Neuroscience for Medical Innovation symposium, experts in multiple areas of neuroscience considered key questions in the field, in particular those related to the importance of neuronal plasticity. The discussions were used as a basis to propose steps that can be taken to improve the effectiveness of drug discovery for psychiatric disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The mechanistic heterogeneity that potentially underlies the existing classification scheme might be limiting our ability to clarify etiology and identify novel therapeutics for several psychiatric illnesses (3).”
From Distinct neuropsychological subgroups in typically developing youth inform heterogeneity in children with ADHD (2012) · cites this paper as [3]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Neuronal Oscillations in Cortical Networks
Buzsáki, G., & Draguhn, A. (2004) · Science · doi:10.1126/science.1099745 · Cited by 6,576
Self-citationDeep Brain Stimulation for Treatment-Resistant Depression
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., Schwalb, J. M., & Kennedy, S. H. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.014 · Cited by 4,059
Self-citationMayberg, H. S., Liotti, M., Brannan, S. K., McGinnis, S., Mahurin, R. K., Jerabek, P. A., Silva, J. A., Tekell, J. L., Martin, C. C., Lancaster, J. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.675 · Cited by 2,416
Self-citationChanges in grey matter induced by training
Draganski, B., Gaser, C., Busch, V., Schuierer, G., Bogdahn, U., & May, A. (2004) · Nature · doi:10.1038/427311a · Cited by 2,373 · cited 1×
“Specific focal structural changes have been found; for example, related to visuo-spatial memory usage in London taxi-drivers and in training motor skill”
BackgroundDopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Carlsson, A., & Lindqvist, M. (1963) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1963.tb01730.x · Cited by 2,148
Pezawas, L., Meyer-Lindenberg, A., Drabant, E. M., Verchinski, B. A., Munoz, K. E., Kolachana, B. S., Egan, M. F., Mattay, V. S., Hariri, A. R., & Weinberger, D. R. (2005) · Nature Neuroscience · doi:10.1038/nn1463 · Cited by 1,980
Self-citationLarge-scale recording of neuronal ensembles
Buzsáki, G. (2004) · Nature Neuroscience · doi:10.1038/nn1233 · Cited by 1,875
Self-citation
Research works printed but not linked: 1
- O'Donnell, P. & Grace, A. A. in Review of Psychiatry Vol 18: Schizophrenia in a Molecular Age. Ed. Tamminga, C. A. 109–140 (American Psychiatric Press, Washington DC, 1999).
Cited by
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Self-citationSubcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression
Lozano, A. M., Mayberg, H. S., Giacobbe, P., Hamani, C., Craddock, R. C., & Kennedy, S. H. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.034 · Cited by 1,024
Self-citationTargeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Self-citationScaling Brain Size, Keeping Timing: Evolutionary Preservation of Brain Rhythms
Buzsáki, G., Logothetis, N., & Singer, W. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.002 · Cited by 886
Self-citationZebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation
Rihel, J., Prober, D. A., Arvanites, A., Lam, K., Zimmerman, S., Jang, S., Haggarty, S. J., Kokel, D., Rubin, L. L., Peterson, R. T., et al. (2010) · Science · doi:10.1126/science.1183090 · Cited by 778
Water associated zero maze: a novel rat test for long term traumatic re-experiencing
Ritov, G., & Richter-Levin, G. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00001 · Cited by 579
Self-citationBuzsáki, G., & Watson, B. O. (2012) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2012.14.4/gbuzsaki · Cited by 579
Self-citationRapid behavior-based identification of neuroactive small molecules in the zebrafish
Kokel, D., Bryan, J., Laggner, C., White, R., Cheung, C. Y. J., Mateus, R., Healey, D., Kim, S., Werdich, A. A., Haggarty, S. J., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.307 · Cited by 534
The subcallosal cingulate gyrus in the context of major depression
Hamani, C., Mayberg, H., Stone, S., Laxton, A., Haber, S., & Lozano, A. M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.034 · Cited by 508
Self-citationMeasuring thigmotaxis in larval zebrafish
Schnörr, S. J., Steenbergen, P. J., Richardson, M. K., & Champagne, D. L. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.12.016 · Cited by 473
Fair, D. A., Bathula, D., Nikolas, M. A., & Nigg, J. T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115365109 · Cited by 464
Evaluation of animal models of neurobehavioral disorders
van der Staay, F. J., Arndt, S. S., & Nordquist, R. E. (2009) · Behavioral and Brain Functions · doi:10.1186/1744-9081-5-11 · Cited by 296
Cognitive dysfunction in depression: Neurocircuitry and new therapeutic strategies
Murrough, J. W., Iacoviello, B., Neumeister, A., Charney, D. S., & Iosifescu, D. V. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.06.006 · Cited by 307
Neurobiological and clinical effects of the antidepressant tianeptine
Kasper, S., & McEwen, B. S. (2008) · CNS Drugs · doi:10.2165/00023210-200822010-00002 · Cited by 302
“in neuroplasticity reflects a new direction for antidepressant therapy.[31,32] 1.”
Musazzi, L., Milanese, M., Farisello, P., Zappettini, S., Tardito, D., Barbiero, V. S., Bonifacino, T., Mallei, A., Baldelli, P., Racagni, G., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008566 · Cited by 289
Self-citationZebrafish embryos and larvae: A new generation of disease models and drug screens
Ali, S., Champagne, D. L., Spaink, H. P., & Richardson, M. K. (2011) · Birth Defects Research Part C: Embryo Today: Reviews · doi:10.1002/bdrc.20206 · Cited by 257
GABA Neuron Alterations, Cortical Circuit Dysfunction and Cognitive Deficits in Schizophrenia
Gonzalez-Burgos, G., Fish, K. N., & Lewis, D. A. (2011) · Neural Plasticity · doi:10.1155/2011/723184 · Cited by 246
Oligodendrocyte lineage cells and depression
Zhou, B., Zhu, Z., Ransom, B. R., & Tong, X. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00930-0 · Cited by 242
Steenbergen, P. J., Richardson, M. K., & Champagne, D. L. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.03.025 · Cited by 224
Novel Drugs and Therapeutic Targets for Severe Mood Disorders
Mathew, S. J., Manji, H. K., & Charney, D. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301652 · Cited by 223
Self-citationThe Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities
Carpenter, W. T., & Koenig, J. I. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301639 · Cited by 206
The use of the zebrafish model in stress research
Steenbergen, P. J., Richardson, M. K., & Champagne, D. L. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.10.010 · Cited by 197
Identifying blood biomarkers for mood disorders using convergent functional genomics
Le-Niculescu, H., Kurian, S. M., Yehyawi, N., Dike, C., Patel, S. D., Edenberg, H. J., Tsuang, M. T., Salomon, D. R., Nurnberger, J. I., & Niculescu, A. B. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.11 · Cited by 211
Sales, A. J., Fogaça, M. V., Sartim, A. G., Pereira, V. S., Wegener, G., Guimarães, F. S., & Joca, S. R. L. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1143-4 · Cited by 198
Cellular and molecular mechanisms in the long-term action of antidepressants.
Racagni, G., & Popoli, M. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.4/gracagni · Cited by 192
“The reasons for this are multiple and have been analyzed in recent reviews.(3,10,112) We believe that four factors have been particularly important for the lack of success in the development of new drugs for psychiatric disorders: (i) lack of adequate diagnostic classification; (ii) lack of adequate animal models; (ii…”
BackgroundSelf-citationReduced somatostatin in subgenual anterior cingulate cortex in major depression
Tripp, A., Kota, R. S., Lewis, D. A., & Sibille, E. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.01.014 · Cited by 190
The pipeline and future of drug development in schizophrenia
Gray, J. A., & Roth, B. L. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002062 · Cited by 184
Wafford, K. A., van Niel, M. B., Ma, Q., Horridge, E., Herd, M. B., Peden, D. R., Belelli, D., & Lambert, J. J. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.004 · Cited by 158
Self-citationZebrafish embryos and larvae in behavioural assays
Tegelenbosch, R. A. J., Noldus, L. P. J. J., Richardson, M. K., & Ahmad, F. (2012) · Behaviour · doi:10.1163/1568539x-00003020 · Cited by 160
Mood, Anxiety, and Serum IGF-1 in Elderly Men Given 24 Weeks of High Resistance Exercise
Cassilhas, R. C., Antunes, H. K. M., Tufik, S., & de Mello, M. T. (2010) · Perceptual and Motor Skills · doi:10.2466/pms.110.1.265-276 · Cited by 137
Comparability of behavioural assays using zebrafish larvae to assess neurotoxicity
Legradi, J., Abdellaoui, N., van Pomeren, M., & Legler, J. (2014) · Environmental Science and Pollution Research · doi:10.1007/s11356-014-3805-8 · Cited by 152
Wong, E. H. F., Yocca, F., Smith, M. A., & Lee, C.-M. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000866 · Cited by 134
Behavioral screening for neuroactive drugs in zebrafish
Rihel, J., & Schier, A. F. (2011) · Developmental Neurobiology · doi:10.1002/dneu.20910 · Cited by 143
Behavioral profiling of zebrafish embryos exposed to a panel of 60 water-soluble compounds
Ali, S., Champagne, D. L., & Richardson, M. K. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.11.020 · Cited by 145
Kara, N., Stukalin, Y., & Einat, H. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.11.003 · Cited by 133
Sartori, C. R., Vieira, A. S., Ferrari, E. M., Langone, F., Tongiorgi, E., & Parada, C. A. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.02.055 · Cited by 140
San, L., & Arranz, B. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.04.002 · Cited by 117
Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders
Machado-Vieira, R., Salvadore, G., Ibrahim, L., Diaz-Granados, N., & Zarate Jr., C. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168010 · Cited by 118
Stress, glucocorticoids and glutamate release: Effects of antidepressant drugs
Musazzi, L., Racagni, G., & Popoli, M. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.05.002 · Cited by 128
Self-citationDoyle, O., Simoni, S. D., Schwarz, A. J., Brittain, C., O’Daly, O., Williams, S., & Mehta, M. A. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201665 · Cited by 116
Pharmacogenetics of antidepressants
Crisafulli, C., Fabbri, C., Porcelli, S., Drago, A., Spina, E., De Ronchi, D., & Serretti, A. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00006 · Cited by 113
Synaptic UNC13A protein variant causes increased neurotransmission and dyskinetic movement disorder
Lipstein, N., Verhoeven-Duif, N. M., Michelassi, F. E., Calloway, N., van Hasselt, P. M., Pienkowska, K., van Haaften, G., van Haelst, M. M., van Empelen, R., Cuppen, I., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90259 · Cited by 114
Hashimoto, H., Hashimoto, R., Shintani, N., Tanaka, K., Yamamoto, A., Hatanaka, M., Guo, X., Morita, Y., Tanida, M., Nagai, K., et al. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06168.x · Cited by 108
Andrade e Silva, B., Cassilhas, R. C., Attux, C., Cordeiro, Q., Gadelha, A. L., Telles, B. A., Bressan, R. A., Ferreira, F. N., Rodstein, P. H., Daltio, C. S., et al. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1595 · Cited by 94
Stewart, A., Grieco, F., Tegelenbosch, R. A. J., Kyzar, E. J., Nguyen, M., Kaluyeva, A. A., Song, C., Noldus, L. P. J. J., & Kalueff, A. V. (2015) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2015.07.023 · Cited by 100
Markham, A., Cameron, I., Bains, R., Franklin, P., Kiss, J. P., Schwendimann, L., Gressens, P., & Spedding, M. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07965.x · Cited by 97
Self-citationHe, L.-W., Zeng, L., Tian, N., Li, Y., He, T., Tan, D.-M., Zhang, Q., & Tan, Y. (2020) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12107 · Cited by 84
Ketamine’s antidepressant effect is mediated by energy metabolism and antioxidant defense system
Weckmann, K., Deery, M. J., Howard, J. A., Feret, R., Asara, J. M., Dethloff, F., Filiou, M. D., Iannace, J., Labermaier, C., Maccarrone, G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16183-x · Cited by 87
Zhang, H., Etherington, L.-A., Hafner, A.-S., Belelli, D., Coussen, F., Delagrange, P., Chaouloff, F., Spedding, M., Lambert, J. J., Choquet, D., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.80 · Cited by 94
Self-citationLearning to identify CNS drug action and efficacy using multistudy fMRI data
Duff, E. P., Vennart, W., Wise, R. G., Howard, M. A., Harris, R. E., Lee, M., Wartolowska, K., Wanigasekera, V., Wilson, F. J., Whitlock, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3008438 · Cited by 90
Qi, H., Mailliet, F., Spedding, M., Rocher, C., Zhang, X., Delagrange, P., McEwen, B. S., Jay, T. M., & Svenningsson, P. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.068 · Cited by 97
Self-citationQuinoline- and Isoquinoline-Sulfonamide Analogs of Aripiprazole: Novel Antipsychotic Agents?
Zajdel, P., Partyka, A., Marciniec, K., Bojarski, A. J., Pawłowski, M., & Wesołowska, A. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.158 · Cited by 95
Carboni, L., Becchi, S., Piubelli, C., Mallei, A., Giambelli, R., Razzoli, M., Mathé, A. A., Popoli, M., & Domenici, E. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.019 · Cited by 92
Self-citationNoakes, T. D., & Spedding, M. (2012) · Nature · doi:10.1038/487295a · Cited by 92
Self-citationPerspectives on experimental models of serotonin syndrome in zebrafish
Stewart, A., Cachat, J., Gaikwad, S., Robinson, K. S. L., Gebhardt, M. J., & Kalueff, A. V. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.02.018 · Cited by 90
Lewis, R. W., Mabry, J., Polisar, J. G., Eagen, K. P., Ganem, B., & Hess, G. P. (2010) · Biochemistry · doi:10.1021/bi100119t · Cited by 83
The pharmacological properties of antidepressants
Racagni, G., & Popoli, M. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283311acd · Cited by 83
Self-citationLazarevic, V., Yang, Y., Flais, I., & Svenningsson, P. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01246-3 · Cited by 81
Self-citationRyan, B., Musazzi, L., Mallei, A., Tardito, D., Gruber, S. H. M., El Khoury, A., Anwyl, R., Racagni, G., Mathé, A. A., Rowan, M. J., et al. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009607 · Cited by 80
Self-citationBiomarkers Predicting Antidepressant Treatment Response: How Can We Advance the Field?
Labermaier, C., Masana, M., & Müller, M. B. (2013) · Disease Markers · doi:10.1155/2013/984845 · Cited by 75
The Role of Genetic Sex in Affect Regulation and Expression of GABA-Related Genes Across Species
Seney, M. L., Chang, L.-C., Oh, H., Wang, X., Tseng, G. C., Lewis, D. A., & Sibille, E. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00104 · Cited by 78
“It should be noted that elevated sgACC activation is not limited to mood disorders, nor is the sgACC the only region exhibiting altered activation in mood disorders; however, this elevated activation and normalization after different modalities of treatment has been consistently shown across many studies [reviewed in…”
ResultBiomarkers for Psychiatric Disorders: Where Are We Standing?
Martins‐de‐Souza, D. (2013) · Disease Markers · doi:10.1155/2013/321071 · Cited by 84
Pharmacogenomics: A road ahead for precision medicine in psychiatry
Pardiñas, A. F., Owen, M. J., & Walters, J. (2021) · Neuron · doi:10.1016/j.neuron.2021.09.011 · Cited by 90
Pittaluga, A., Raiteri, L., Longordo, F., Luccini, E., Barbiero, V. S., Racagni, G., Popoli, M., & Raiteri, M. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.04.006 · Cited by 77
Self-citationThe nucleus accumbens: a target for deep brain stimulation in resistant major depressive disorder
Nauczyciel, C., Robic, S., Dondaine, T., Verin, M., Robert, G., Drapier, D., Naudet, F., & Millet, B. (2013) · Journal of Molecular Psychiatry · doi:10.1186/2049-9256-1-17 · Cited by 73
Terbeck, S., Akkus, F., Chesterman, L. P., & Hasler, G. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00086 · Cited by 70
Eriksson, T. M., Delagrange, P., Spedding, M., Popoli, M., Mathé, A. A., Ögren, S. O., & Svenningsson, P. (2012) · Molecular Psychiatry · doi:10.1038/mp.2010.131 · Cited by 73
Self-citationSchultz, L., Zurich, M., Culot, M., Costa, A. D., Landry, C., Bellwon, P., Kristl, T., Hörmann, K., Ruzek, S., Aiche, S., et al. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.05.016 · Cited by 81
Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
Lozano, A. M., Mayberg, H. S., Giacobbe, P., Hamani, C., Craddock, R. C., & Kennedy, S. H. (2010) · Focus · doi:10.1176/foc.8.4.foc583 · Cited by 72
Self-citationZhao, W.-N., Cheng, C., Theriault, K. M., Sheridan, S. D., Tsai, L.-H., & Haggarty, S. J. (2012) · SLAS Discovery · doi:10.1177/1087057112456876 · Cited by 71
Bhagya, V. R., Srikumar, B. N., Raju, T. R., & Rao, B. S. S. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2054-x · Cited by 76
A mouse model of anxiety molecularly characterized by altered protein networks in the brain proteome
Szegő, É. M., Janáky, T., Szabó, Z., Csorba, A., Kompagne, H., Müller, G., Lévay, G. I., Simor, A., Juhász, G. D., & Kékesi, K. A. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.11.003 · Cited by 75
Kalinichev, M., & Dawson, L. A. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001495 · Cited by 68
Frazzetto, G., & Anker, S. (2009) · Nature reviews. Neuroscience · doi:10.1038/nrn2736 · Cited by 70
Perspectives on Zebrafish Models of Hallucinogenic Drugs and Related Psychotropic Compounds
Neelkantan, N., Mikhaylova, A., Stewart, A., Arnold, R., Gjeloshi, V., Kondaveeti, D., Poudel, M. K., & Kalueff, A. V. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400090q · Cited by 69
Surgery for Psychiatric Disorders
Luigjes, J., de Kwaasteniet, B. P., de Koning, P. P., Oudijn, M. S., van den Munckhof, P., Schuurman, P. R., & Denys, D. A. J. P. (2012) · World Neurosurgery · doi:10.1016/j.wneu.2012.03.009 · Cited by 73
Sales, A. J., & Joca, S. R. L. (2016) · Acta Neuropsychiatrica · doi:10.1017/neu.2015.40 · Cited by 62
“However, it has been shown that decitabine (5-AzaD) decreases DNA methylation and increases BDNF expression in the HPC (29), an effect that has been recognised as necessary for the behavioural effect of conventional antidepressant drugs (41,45).”
BackgroundSex Differences in Depression and Anxiety
Pavlidi, P., Kokras, N., & Dalla, C. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_375 · Cited by 63
Liu, J., Cheng, Y., Li, M., Zhang, Z., Li, T., & Luo, X. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01456-5 · Cited by 66
Lin, X., Duan, X., Jacobs, C. S., Ullmann, J. F. P., Chan, C.-Y., Chen, S., Cheng, S. H., Zhao, W.-N., Poduri, A., Wang, X., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07289-5 · Cited by 60
Chávez-Castillo, M., Núñez, V., Nava, M., Ortega, Á., Rojas, M., Bermúdez, V., & Rojas, J. (2019) · Advances in Pharmacological Sciences · doi:10.1155/2019/7943481 · Cited by 71
Time to recognize zebrafish ‘affective’ behavior
Vernier, P., Kyzar, E. J., Maximino, C., Tierney, K. B., Gebhardt, M. J., Lange, M., Jesuthasan, S. J., Stewart, A., Neuhauss, S. C. F., Robinson, K. S. L., et al. (2012) · Behaviour · doi:10.1163/1568539x-00003030 · Cited by 59
Publication Bias and the Efficacy of Antidepressants
Mathew, S. J., & Charney, D. S. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08071102 · Cited by 63
Bianchi, M. T., Pathmanathan, J. S., & Cash, S. S. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.09.049 · Cited by 59
Tanaka, M. (2025) · Biomedicines · doi:10.3390/biomedicines13010167 · Cited by 42
Biological substrates underpinning diagnosis of major depression
Sibille, E., & French, B. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000436 · Cited by 50
Musazzi, L., Mallei, A., Tardito, D., Gruber, S., Khoury, A. E., Racagni, G., Mathé, A., & Popoli, M. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.11.008 · Cited by 52
Self-citationMusazzi, L., Milanese, M., Farisello, P., Zappettini, S., Tardito, D., Barbiero, V. S., Bonifacino, T., Mallei, A., Baldelli, P., Racagni, G., et al. (2010) · PLoS ONE · doi:10.1371/annotation/101dd9d3-4e1b-4863-9473-bbfef49c9a1d · Cited by 52
Self-citationGlutamate-based depression GBD
McCarthy, D. J., Alexander, R., Smith, M. A., Pathak, S., Kanes, S., Lee, C., & Sanacora, G. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.02.009 · Cited by 54
Gressèns, P., Schwendimann, L., Husson, I., Sárközy, G., Mocaër, E., Vamecq, J., & Spedding, M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.04.016 · Cited by 51
Self-citationZebrafish as an In Vivo High-Throughput Model for Genotoxicity
Chakravarthy, S., Sadagopan, S., Nair, A. R., & Sukumaran, S. K. (2014) · Zebrafish · doi:10.1089/zeb.2013.0924 · Cited by 57
The interaction between the internal clock and antidepressant efficacy
Racagni, G., Riva, M. A., & Popoli, M. (2007) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000277957.75852.c7 · Cited by 49
Self-citationLeuthold, D., Klüver, N., Altenburger, R., & Busch, W. (2018) · Environmental Science & Technology · doi:10.1021/acs.est.8b04327 · Cited by 47
The Emerging Use of Technology for the Treatment of Depression and Other Neuropsychiatric Disorders
Howland, R. H., Shutt, L. S., Berman, S. R., Spotts, C. R., & Denko, T. (2011) · Annals of Clinical Psychiatry · doi:10.1177/104012371102300108 · Cited by 46
Piser, T. M. (2010) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2010.02.006 · Cited by 50
Liang, B., Huang, F., Wang, H., Wang, G., Yuan, X., Zhang, M.-Z., Guo, H., Cheng, Y., & Xu, J. (2014) · Pharmaceutical Biology · doi:10.3109/13880209.2014.922586 · Cited by 48
Early induction of CREB activation and CREB-regulating signalling by antidepressants
Tardito, D., Musazzi, L., Tiraboschi, E., Mallei, A., Racagni, G., & Popoli, M. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000376 · Cited by 42
Self-citationAligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery
McArthur, R. A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.02.004 · Cited by 42
Milanese, M., Tardito, D., Musazzi, L., Treccani, G., Mallei, A., Bonifacino, T., Gabriel, C., Mocaër, E., Racagni, G., Popoli, M., et al. (2013) · BMC Neuroscience · doi:10.1186/1471-2202-14-75 · Cited by 43
Self-citation
Metadata
- Authors
- Agid, Y., Buzsáki, G., Diamond, D. M., Frackowiak, R., Giedd, J., Girault, J.-A., Grace, A., Lambert, J. J., Manji, H., Mayberg, H., Popoli, M., Prochiantz, A., Richter-Levin, G., Somogyi, P., Spedding, M., Svenningsson, P., & Weinberger, D.
- Affiliations
- Inserm (FR)
- Rutgers, The State University of New Jersey (US)
- University of South Florida (US)
- National Hospital for Neurology and Neurosurgery (GB)
- National Institutes of Health (US)
- University of Pittsburgh (US)
- University of Dundee (GB)
- Emory University (US)
- University of Milan (IT)
- Centre National de la Recherche Scientifique (FR)
- Karolinska Institutet (SE)
- Corresponding author
- Spedding, Michael
- ORCID
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-03
- Volume
- 6
- Issue
- 3
- Pages
- 189-201
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2039643193
- Semantic Scholar
- 6b055b58cc82aab9331b179042a3985bb06b3e33
- Cited by
- 240
- References
- 81
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 5 · 2023: 3 · 2022: 12 · 2021: 7 · 2020: 7 · 2019: 8 · 2018: 10 · 2017: 9 · 2016: 3 · 2015: 8 · 2014: 10 · 2013: 17 · 2012: 30
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons - University of South Florida (University of South Florida) (submittedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- psychiatric drug discovery, depression, schizophrenia, anxiety, neuropsychiatric disorders, neuroplasticity, translational neuroscience, multidisciplinary approach
- MeSH terms
- Mental Disorders, Consensus Statements as Topic, Humans, Models, Biological, Surveys and Questionnaires, Tranquilizing Agents, Drug Design, Signal Transduction, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.